Benign prostatic hyperplasia (BPH) is a common condition where the prostate becomes enlarged. This can lead to urinary symptoms such as a frequent or urgent need to urinate and difficulty starting or completing urination. Urologic Disease in America reports approximately 200,000 Emergency Room admissions per year with BPH as a primary diagnosis between 2002-2007.3
The prevalence of BPH increases with age, affecting an estimated 50% of men over the age of 604 and BPH is associated with reduced quality of life.5 However, patients often consider current treatments to be unsatisfactory because of side-effects, including sexual dysfunction.5 These may also reduce quality of life5 despite an improvement in urinary symptoms. For this reason, adherence to treatments remains low.6
Benign prostatic hyperplasia is usually diagnosed by measuring the level of prostate specific antigen (PSA) in the blood, and by feeling for abnormalities in the prostate during a digital rectal examination.7 Additional tests, for example a urine test, may also be used to confirm a BPH diagnosis and rule out other, more severe conditions.
Lifestyle modifications such as drinking fewer liquids may be attempted to manage BPH symptoms; however, BPH treatment usually requires pharmaceutical intervention. Three different classes of pharmaceutical agents can be used to treat BPH, and they are often prescribed concurrently. These are:7 Alpha-receptor blockers to relax the muscles in the prostate and bladder, which may alleviate symptoms;7 5-alpha reductase inhibitors (5-ARIs) to shrink the prostate;7 and phosphodiesterase 5 inhibitors (PDE5 inhibitors) which help to increase urinary flow.7 In severe cases, surgery may be required.